CA2137832C - Inhibitors of angiotensin i chymase(s) including human heart chymase - Google Patents

Inhibitors of angiotensin i chymase(s) including human heart chymase Download PDF

Info

Publication number
CA2137832C
CA2137832C CA002137832A CA2137832A CA2137832C CA 2137832 C CA2137832 C CA 2137832C CA 002137832 A CA002137832 A CA 002137832A CA 2137832 A CA2137832 A CA 2137832A CA 2137832 C CA2137832 C CA 2137832C
Authority
CA
Canada
Prior art keywords
formula
alkyl
product
ethyl acetate
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002137832A
Other languages
English (en)
French (fr)
Other versions
CA2137832A1 (en
Inventor
Dennis J. Hoover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CA2137832A1 publication Critical patent/CA2137832A1/en
Application granted granted Critical
Publication of CA2137832C publication Critical patent/CA2137832C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002137832A 1992-06-12 1993-04-23 Inhibitors of angiotensin i chymase(s) including human heart chymase Expired - Fee Related CA2137832C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89772392A 1992-06-12 1992-06-12
US897,723 1992-06-12
PCT/US1993/003625 WO1993025574A1 (en) 1992-06-12 1993-04-23 Inhibitors of angiotensin i chymase(s) including human heart chymase

Publications (2)

Publication Number Publication Date
CA2137832A1 CA2137832A1 (en) 1993-12-23
CA2137832C true CA2137832C (en) 2000-09-26

Family

ID=25408314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137832A Expired - Fee Related CA2137832C (en) 1992-06-12 1993-04-23 Inhibitors of angiotensin i chymase(s) including human heart chymase

Country Status (5)

Country Link
EP (1) EP0644892A1 (fi)
JP (1) JP2668003B2 (fi)
CA (1) CA2137832C (fi)
FI (1) FI932695A (fi)
WO (1) WO1993025574A1 (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524267D0 (en) * 1995-11-28 1996-01-31 Isis Innovation Enzyme inhibitor and method
EA004037B1 (ru) * 1996-09-10 2003-12-25 Др. Карл Томэ ГмбХ Модифицированные аминокислоты и лекарственное средство на их основе
UA79749C2 (en) * 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SI0932617T1 (en) * 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6080738A (en) * 1996-10-25 2000-06-27 Yoshitomi Pharmaceuticals Industries, Ltd. Heterocyclic amide compounds and medicinal uses thereof
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CN1209368C (zh) 1998-02-17 2005-07-06 日本化药株式会社 新的乙酰胺衍生物及其用途
CA2341195A1 (en) * 1998-08-20 2000-03-02 Mitsunori Waki Prophylactic or therapeutic composition for ocular circulation disorders
EP1136488A4 (en) * 1998-12-01 2002-06-12 Meiji Seika Kaisha SF2809-I, II, III. VI, V AND VI COMPOUNDS WITH CHYMASE INHIBITING EFFECT
ATE360423T1 (de) 1999-11-01 2007-05-15 Daiichi Asubio Pharma Co Ltd Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
ATE352317T1 (de) 2000-02-22 2007-02-15 Daiichi Asubio Pharma Co Ltd Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
CN1366461A (zh) 2000-02-22 2002-08-28 三得利株式会社 含有胃促胰酶抑制剂作为有效成分的预防或治疗纤维变性的药物
DE60121695T2 (de) 2000-02-22 2007-08-30 Daiichi Asubio Pharma Co., Ltd. Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
EP1284266A4 (en) * 2000-05-02 2005-11-16 Meiji Seika Kaisha NEW INDOIND DERIVATIVES WITH CHYME-INHIBITABLE ACTIVITIES AND METHOD FOR THEIR PREPARATION
WO2002006280A2 (en) * 2000-07-13 2002-01-24 Millennium Pharamaceuticals, Inc. INHIBITORS OF FACTOR Xa
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
US6982348B2 (en) 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
US20060217421A1 (en) 2003-05-09 2006-09-28 Hajimu Kurumatani Fortifier
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CA2657618C (en) 2006-07-13 2016-10-11 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CN102245599B (zh) 2008-12-10 2014-05-14 艾其林医药公司 作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
EP2970192A1 (en) 2013-03-15 2016-01-20 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC CARBOCYCLIC PROLINAMIDE DERIVATIVES
JP7179721B2 (ja) 2016-06-21 2022-11-29 オリオン・オフサルモロジー・エルエルシー 複素環式プロリンアミド誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
CA2021660A1 (en) * 1989-07-26 1991-01-27 Philippe Bey Peptidase inhibitors
DE69229552T2 (de) * 1991-05-23 1999-12-23 Merrell Pharma Inc Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau

Also Published As

Publication number Publication date
CA2137832A1 (en) 1993-12-23
FI932695A0 (fi) 1993-06-11
JP2668003B2 (ja) 1997-10-27
FI932695A (fi) 1993-12-13
EP0644892A1 (en) 1995-03-29
WO1993025574A1 (en) 1993-12-23
JPH07507069A (ja) 1995-08-03

Similar Documents

Publication Publication Date Title
CA2137832C (en) Inhibitors of angiotensin i chymase(s) including human heart chymase
RU2142469C1 (ru) Пептидные производные, их стереоизомеры или физиологически приемлемые соли, обладающие противотромбозной, противосвертывающей или противовоспалительной активностью, способ их получения, фармацевтическая композиция, способ подавления тромбина, способ подавления кининогеназ, применение соединений в качестве исходных в синтезе ингибитора тромбина
KR900008004B1 (ko) 펩티다제 억제물의 제조방법
US6992105B2 (en) Dipeptide derivatives
US5430023A (en) Tripeptide antithrombotic agents
US6432921B2 (en) Thrombin inhibitors
US20060194742A1 (en) Pyrane derivatives as both ACE- and NEP-inhibitors
AU2002314067A1 (en) Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors
US6218365B1 (en) Serine protease inhibitors
PL188411B1 (pl) Nowe inhibitory trombiny i ich zastosowanie
HUT61744A (en) Process for producing renin inhibiting alkylaminocarbonyl group-substituted heterocyclic compounds
CA2006839A1 (en) Renin inhibitors containing c-terminal dihydroxy amides
CA2013475A1 (en) Amino acid derivatives
JPH0688979B2 (ja) 化合物
RU2172321C2 (ru) Ингибиторы сериновых протеаз
KR880001007B1 (ko) 비사이클릭 화합물의 제조 방법
JPH01110695A (ja) アミノ酸誘導体その製造方法及び血圧降下剤
INAGAKI et al. P1—P1’Cleavage Site “
MXPA98007090A (en) Inhibitors of serine prote

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed